

Case Report

https://doi.org/10.3947/ic.2016.48.4.338 Infect Chemother 2016;48(4):338-341 ISSN 2093-2340 (Print) · ISSN 2092-6448 (Online)



Severe Fever with Thrombocytopenia Syndrome Presenting with Hemophagocytic Lymphohistiocytosis

Jongmin Lee¹, Gyeongmin Jeong¹, Ji-Hun Lim², Hawk Kim³, Sun-Whan Park⁴, Won-Ja Lee⁴, and Jae-Bum Jun¹

¹Department of Internal Medicine, ²Department of Laboratory Medicine, ³Division of Hematology and Hematological Malignancies, Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan; ⁴Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Korea

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by the newly discovered SFTS Bunyavirus, and there have been no case reports of SFTS patients presenting with hemophagocytic lymphohistiocytosis (HLH) in the English literature. We report a case of SFTS presenting with HLH in a 73-year-old immunocompetent male farmer. Although the patient had poor prognostic factors for SFTS, such as old age and central nervous system symptoms, he recovered fully with supportive care.

Key Words: Severe fever with thrombocytopenia syndrome; Bunyavirus; Hemophagocytic lymphohistiocytosis

Introduction

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by the newly discovered SFTS Bunyavirus (SFTSV) [1]. SFTS can be life threatening and is characterized by sudden onset of fever, thrombocytopenia, gastrointestinal symptoms, and leukopenia. First identified in China in 2010, cases of SFTS have also been reported in South Korea and Japan since 2013 [1-3]. While the mortality rate of SFTS reported in China ranges from 6 to 12%, the mortality rate in South Korea and Japan is much higher at 45 to 55%, although the patient population of these two countries is relatively small [1, 2, 4, 5].

Hemophagocytic lymphohisticytosis (HLH) is another potentially fatal syndrome involving pathological immune activation, which is characterized by clinical signs and symptoms of extreme inflammation [6]. It is associated with a variety of infections, among which Epstein–Barr virus (EBV) is the most frequent cause.

Upon examining the relevant clinical literature published, we found a few publications reporting patients with SFTS presenting with HLH [7, 8]. So far, there has been no case report on SFTS associated with HLH in the English literature. Herein, we report the first case of SFTS associated with HLH in Korea.

Received: March 12, 2016 Accepted: May 8, 2016 Published online: November 11, 2016

Corresponding Author: Jae-Bum Jun, MD

Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of

Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan 44033, Korea


Tel: +82-52-250-8930, Fax: +82-52-250-7048

E-mail: uvgotletter@hanmail.net

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.







Case report

On July 2, 2013, a 73-year-old male farmer, residing in the countryside near Ulsan, South Korea, developed fever. His fever did not subside over the next 3 days, so he was admitted to a local hospital on July 5. One day after admission, the patient experienced a sudden drop in blood pressure. Thus, the patient was transferred to our facility (Ulsan University Hospital. an 800-bed teaching hospital), while receiving dopamine infusions.

When the patient was admitted to our facility, he was awake and alert. The patient had myalgia, headache, and diarrhea with a frequency of 3-4 times per day. He had no medical history other than a 10-year history of hypertension, for which he took medication. The patient did not recall being bitten by any insect. Physical examination revealed no lymph node enlargement or rash. His temperature was 38.5°C, blood pressure 122/70 mmHg with dopamine infusions at the rate of a 10 µg/ kg/min, and heart rate 87 beats per minute. Laboratory test results showed bicytopenia and elevated serum aspartate aminotransferase, alanine aminotransferase, creatinine kinase, lactate dehydrogenase, and ferritin (Table 1). Prothrombin time, activated partial prothrombin time, and C-reactive protein levels revealed normal results. A neck, chest, and abdominal computed tomography (CT) scan did not reveal any abnormal findings. Ceftriaxone and doxycycline therapy was started on the first day of admission.

On the second day of admission, the patient's blood pressure stabilized; thus, we stopped the dopamine infusion. However, the patient became drowsy and disoriented regarding time and location, although he was able to recognize the persons around him. Cerebrospinal fluid analysis revealed no erythrocytes or leukocytes, and chemistry profile was normal. Brain CT showed no signs of hemorrhage, infarction, or other abnor-




Figure 1. The smear of the bone marrow aspiration showed hemophagocytosis of erythroid (arrow) and myeloid precursors (arrowhead) by histiocytes (Wright-Giemsa stain, ×1,000).

Table 1. Laboratory test results of the patient

Laboratory test (reference range)	Day 1	Day 3	Day 6	Day 8	Day 11
Hemoglobin, g/dL (14–18)	13.3	13.5	13.9	12.8	11.6
Leukocytes, cells/mm³(4,000-10,000)	950	1,350	2,550	4,460	4,530
Neutrophils, % (36–66)	35	59	24	55	44
Lymphocytes, % (22–40)	52	21	32	18	23
Monocytes, % (2–10)	11	4	36	26	30
Platelets, /mm ³ (140–400)	64,000	97,000	51,000	83,000	265,000
AST, IU/L (15-40)	64	432	257	131	45
ALT, IU/L (0-40)	39	165	99	77	54
CRP, mg/dL (0-0.5)	0.40	0.20	0.24	6.22	1.66
Ferritin, ng/mL (22–322)	NA	9,601	NA	NA	NA
LDH, IU/L (218–472)	615	2120	NA	NA	NA
Creatinine kinase, IU/L (55–227)	497	791	3690	482	94
Creatinine, mg/dL (0.6–1.5)	1.44	1.08	1.03	0.94	0.89
aPTT, sec (21.0-39.4)	38.0	44.9	35.4	NA	NA
Prothrombin time, INR (0.84–1.16)	0.95	0.92	0.73	NA	NA

AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, c-reactive protein; LDH, lactate dehydrogenase; aPTT, activated partial thromboplastin time; INR, International normalized ratio; NA, not available.




Figure 2. Phylogenetic analysis of the SFTSV KAGBH3 strain (the strain from our patient) based on the partial viral genome sequences (560 bp), which were included in glycoprotein Gn of M segment sequences (A) and nucleocapsid protein of S segment sequences (B). The phylogenetic trees that are shown were generated by MEGA version 5.2 software from aligned nucleotide sequences of 16 isolates of phleboviruses, including the identified SFTSV. Heartland virus was used as the outgroup. The phylogenetic analysis is comparing M and S partial nucleotide sequences of SFTSV KAGBH3 strain with homologous sequences of previously characterized SFTSVs. Sequences were analyzed by the neighbor-joining method based on the maximum composite likelihood model. The minimal length trees shown were supported as the majority rule consensus tree in 5,000 replicates. The bootstrap replicates supporting each node are indicated. KAGBH3 strain is marked with black circles.

malities. Bone marrow was examined because of the presence of pancytopenia. Bone marrow aspirate revealed proliferation of histiocytes with prominent hemophagocytosis. (Fig. 1). Natural killer (NK) cell activity had decreased to 7.6% (normal range: 18–40%) and triglyceride levels had increased to 320 mg/dl (normal range: 0–250 mg/dL). However, fibrinogen was normal at 262 mg/dL (normal range: 200–400 mg/dL).

Regarding the cause of fever, repeated blood culture and serology test results did not indicate the presence of leptospira, Orientia tsutsugamushi, Hantaan virus, hepatitis A/B/C virus, human immunodeficiency virus, EBV, cytomegalovirus, or parvovirus. On the fifth day of admission, reverse transcriptase polymerase chain reaction (RT-PCR) test results from the Korean Centers for Disease Control and Prevention, which we had requested on the third day of admission, indicated the presence of the SFTSV. At this point, the patient no longer had fever. A phylogenetic tree was constructed by the neighbor-joining method based on the partial M (Fig. 2A) and S segment (Fig. 2B) sequences of the strain from our patient and 15 SFTSVs from China and Japan registered in GenBank. The tree indicated that the strain was closely related to the SFTSV isolates from China and Japan. With supportive care, the patient's mental state had fully recovered by the seventh day of admission. As the white blood cell count, platelet count, and aminotransferase levels had normalized on day 11 of admission, the patient was discharged.

Discussion

Our patient underwent bone marrow biopsy because he presented with a fever of unknown cause with severe neutropenia (absolute neutrophil count of 332/mm³) and thrombocytopenia. He presented with fever, pancytopenia, hyperferritinemia, hypertriglyceridemia, low NK-cell activity, and hemophagocytosis in the bone marrow, fulfilling the diagnostic criteria for HLH [6]. We could find a clinical report that describes patients having SFTS presenting with HLH [8]. Weng et al. reported that among 12 patients diagnosed with SFTS, five cases were confirmed as having HLH [8]. In addition, reports regarding the bone marrow biopsy findings of SFTS patients are available. According to QuanTai et al., among 10 patients who underwent bone marrow biopsy, none exhibited hemophagocytosis in the bone marrow aspirate [7]. In contrast, Takahashi et al. reported that among five SFTS patients who underwent bone marrow biopsy, all five exhibited hemophagocytosis in the bone marrow aspirate [2]. Compared with the rarity of HLH presenting with hemorrhagic fever with renal syndrome due to Hantavirus of the same Bunyaviridae family, SFTS may be commonly accompanied by HLH, as per the reports of Takahashi et al. and Weng et al. [2, 8].

Both SFTS and HLH are potentially life-threatening syndromes. According to Weng et al., two of the five patients that presented with HLH did not survive, and while the number of SFTS patients with HLH is low, their mortality rate of 40% is

quite high. The known factors indicating poor prognosis of SFTS include old age, central nervous system (CNS) symptoms, and disseminated intravascular coagulation [1-4]. Poor prognostic factors for HLH also include old age, CNS symptoms, and high ferritin levels [6, 9]. Although the present patient was old and exhibited CNS symptoms, he recovered fully with supportive care such as inotropic agents and intravenous fluid therapy.

Currently, there is no specific treatment for SFTS other than supportive care, although treatments for patients with HLH whose clinical condition is deteriorating rapidly include chemotherapy and immunotherapy to reduce inflammation [6]. As such, treatments targeting HLH could be considered for SFTS patients with associated HLH whose clinical condition is deteriorating. Thus, if an SFTS patient presents with severe neutropenia and high ferritin levels, a bone marrow biopsy could be conducted to test for the presence of HLH. In this case, the clinical condition of the patient gradually improved, and no treatment, such as chemotherapy or steroids, was administered.

We report a case of a patient with SFTS presenting with HLH, who recovered fully with only supportive care, despite having poor prognostic factors, including old age and altered mental status. We recommend that clinicians consider the possibility of HLH in patients with SFTS presenting with severe neutropenia and high ferritin levels.

Conflicts of Interest

No conflicts of interest.

ORCID

Jongmin Lee http://orcid.org//0000-0002-9220-8874 Jae-Bum Jun http://orcid.org/0000-0001-9752-7682

Reference

1. Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, Ren J, Wang H, Zhao Z, Song

- JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523-32.
- 2. Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, Kamei T, Honda M, Ninomiya D, Sakai T, Senba T, Kaneyuki S, Sakaguchi S, Satoh A, Hosokawa T. Kawabe Y. Kurihara S. Izumikawa K. Kohno S. Azuma T, Suemori K, Yasukawa M, Mizutani T, Omatsu T, Katayama Y, Miyahara M, Ijuin M, Doi K, Okuda M, Umeki K, Saito T, Fukushima K, Nakajima K, Yoshikawa T, Tani H, Fukushi S, Fukuma A, Ogata M, Shimojima M, Nakajima N, Nagata N, Katano H, Fukumoto H, Sato Y, Hasegawa H, Yamagishi T, Oishi K, Kurane I, Morikawa S, Saijo M. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis 2014;209:816-27.
- 3. Kim KH, Yi J, Kim G, Choi SJ, Jun KI, Kim NH, Choe PG, Kim NJ, Lee JK, Oh MD.Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis 2013;19:1892-4.
- 4. Ding F, Zhang W, Wang L, Hu W, Soares Magalhaes RJ, Sun H, Zhou H, Sha S, Li S, Liu Q, Li Q, Yang W, Huang L, Li C,Yin W.Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011-2012. Clin Infect Dis 2013;56:1682-3.
- 5. Shin JS, Park JH, Kwon DH. Epidemiologic and clinical characteristics of severe fever with thrombocytopenia syndrome in the Republic of Korea. Public Health Weekly Report 2014;7:493-8.
- 6. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood 2011;118:4041-52.
- 7. QuanTai X, FengZhe C, XiuGuang S, DongGe C. A study of cytological changes in the bone marrow of patients with severe fever with thrombocytopenia syndrome. PLoS One 2013;8:e83020.
- 8. Weng Y, Chen N, Han Y, Xing Y, Li J. Clinical and laboratory characteristics of severe fever with thrombocytopenia syndrome in Chinese patients. Braz J Infect Dis 2014;18:88-91.
- 9. Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011;118:4577-84.